Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine safety overview

M R Green1

  • 1Hollings Cancer Center, Medical University of South Carolina, Charleston 29425, USA.

Seminars in Oncology
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Gemcitabine, a novel nucleoside analog, demonstrates a favorable safety profile with mild and transient myelosuppression. This analysis of 790 patients across 18 studies confirms its tolerability in various tumor types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Matrix-assisted laser desorption/ionization-collision induced dissociation of poly(styrene).

Journal of the American Society for Mass Spectrometry·2016
Same author

Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.

Blood cancer journal·2015
Same author

BSACI guideline for the diagnosis and management of cow's milk allergy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

The importance of the abdominal X-radiograph in acute ulcerative colitis.

Archives of disease in childhood. Education and practice edition·2014
Same author

Peptide sequence determination by matrix-assisted laser desorption ionization employing a tandem double focusing magnetic-Orthogonal acceleration time-of-flight mass spectrometer.

Journal of the American Society for Mass Spectrometry·2013
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Gemcitabine is a novel nucleoside analog used in cancer therapy.
  • Understanding its toxicity profile is crucial for patient management.

Purpose of the Study:

  • To comprehensively analyze the safety and toxicity data of gemcitabine from single-agent studies.
  • To evaluate the tolerability of gemcitabine across diverse tumor types and patient populations.

Main Methods:

  • Meta-analysis of safety data from 18 single-agent gemcitabine studies.
  • Inclusion of 790 patients treated with gemcitabine at doses of 800-1,250 mg/m² weekly for 3 weeks followed by a 1-week rest.
  • Detailed assessment of adverse events, including myelosuppression, infection, hemorrhage, transaminase levels, renal function, and symptomatic toxicities.

Related Experiment Videos

Main Results:

  • Myelosuppression (hemoglobin, leukocytes, neutrophils, platelets) was generally mild and short-lived, with low rates of World Health Organization grades 3 and 4.
  • Low incidences of infection and hemorrhage were observed.
  • Mild transaminase elevations were common but rarely dose-limiting.
  • Renal toxicity was generally mild, with rare cases of renal failure.
  • Low rates of gastrointestinal and hair toxicities, but a higher than expected incidence of mild flu-like symptoms and edema.
  • Similar toxicity findings in non-small cell lung cancer subgroup analysis.

Conclusions:

  • Gemcitabine exhibits a favorable safety profile with manageable toxicity.
  • The observed adverse events are generally mild and transient, supporting its use as a well-tolerated chemotherapeutic agent.
  • Further research may focus on managing specific side effects like flu-like symptoms and edema.